CRBP - Corbus Pharmaceuticals Holdings, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Corbus Pharmaceuticals Holdings, Inc.

500 River Ridge Drive
Norwood, MA 02062
United States
617-963-0100
http://www.corbuspharma.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees77

Key Executives

NameTitlePayExercisedYear Born
Dr. Yuval CohenCEO & Director837kN/A1975
Dr. Mark A. TepperCo-Founder & Consultant565.5kN/A1957
Dr. Barbara WhiteChief Medical Officer593.6kN/A1950
Mr. Sean F. Moran CPA, M.B.A., CPA, MBAChief Financial OfficerN/AN/A1958
Ted JenkinsSr. Director of Investor Relations & CommunicationsN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid drug that is in Phase 3 clinical trial for the treatment of systemic sclerosis and dermatomyositis, and in Phase 2 clinical trial to treat systemic lupus erythematosus and cystic fibrosis. The company also has a license to develop, manufacture, and market CRB-4001, a 2nd generation peripherally-restricted, CB1 inverse agonist, which is in a preclinical stage to treat liver, lung, heart, and kidney fibrotic diseases. In addition, it has a strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of lenabasum in Japan. The company was founded in 2009 and is based in Norwood, Massachusetts.

Corporate Governance

Corbus Pharmaceuticals Holdings, Inc.’s ISS Governance QualityScore as of June 25, 2019 is 6. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 4; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.